HPPD

HPPD (Hallucinogen Persisting Perception Disorder) is a diagnosable condition in which visual disturbances experienced during hallucinogen use continue, or recur spontaneously, long after the substance has left the body. These can include geometric patterns, trails behind moving objects, halos around light sources, intensified afterimages, and apparent motion in the peripheral field.

Two subtypes are recognised. Type I involves brief, discrete flashbacks — isolated re-experiences of perceptual effects that pass quickly. Type II is more chronic: a near-constant background of visual noise that persists for months or years and can significantly affect daily functioning. Type II is what the diagnosis typically refers to in clinical and research contexts.

How it works · its role

The exact mechanism is not well understood. The leading hypothesis is a loss of inhibitory tone in visual processing pathways — the brain's normal mechanism for filtering out low-level perceptual noise is thought to become underactive, allowing signals that would ordinarily be suppressed to reach conscious awareness.

Some researchers point to lasting changes in cortical excitability, possibly in GABAergic interneurons in the visual cortex. There is also evidence that pre-existing anxiety, migraine with aura, or early depersonalisation symptoms may make someone more susceptible. Whether HPPD reflects a lasting neurological change, an unmasked pre-existing vulnerability, or a conditioned perceptual pattern remains an open question.

Relevance to substances & effects

Classic psychedelics — including LSD, psilocybin-containing mushrooms, and mescaline — are most commonly associated with HPPD, and most research involves these compounds. The condition is not limited to them; MDMA, ketamine, and cannabis have each been reported as precipitating or exacerbating factors in some individuals.

Frequency and dose of use appear to raise risk, though HPPD has been reported after a single exposure. It can emerge immediately after a difficult experience, or surface gradually with no clear trigger. Importantly, most people who use psychedelics do not develop HPPD — prevalence estimates vary widely and reliable figures are difficult to establish given underreporting and diagnostic overlap.

Clinical · risk note

HPPD is distinct from a psychotic episode: the person is typically aware that the perceptions are anomalous, which distinguishes it from hallucinations in the psychiatric sense. This insight does not make it less distressing — for those with Type II, the continuous visual interference can produce significant anxiety, derealization, and impaired concentration.

There is no established first-line treatment. Cessation of all psychoactive substances — including cannabis and stimulants, which can worsen symptoms — is generally the first step. Some clinicians use benzodiazepines or anticonvulsants to reduce cortical excitability; SSRIs are sometimes reported to worsen symptoms and are used cautiously if at all.

Anyone experiencing persisting visual changes after hallucinogen use should seek evaluation to rule out other causes — including migraine aura, occipital epilepsy, and ophthalmological conditions — before a diagnosis of HPPD is made.